Decadron Elixir

Name: Decadron Elixir

Clinical pharmacology

Naturally occurring glucocorticoids, (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs, including dexamethasone, are primarily used for their potent anti-inflammatory effects in disorders of many organ systems.

Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the body's immune responses to diverse stimuli.

At equipotent anti-inflammatory doses, dexamethasone almost completely lacks the sodium-retaining property of hydrocortisone and closely related derivatives of hydrocortisone.

Indications and usage

  1. Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance).
    Congenital adrenal hyperplasia
    Nonsuppurative thyroiditis
    Hypercalcemia associated with cancer
  2. Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:
    Psoriatic arthritis
    Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy)
    Ankylosing spondylitis
    Acute and subacute bursitis
    Acute nonspecific tenosynovitis
    Acute gouty arthritis
    Post-traumatic osteoarthritis
    Synovitis of osteoarthritis
    Epicondylitis
  3. Collagen Diseases: During an exacerbation or as maintenance therapy in selected cases of:
    Systemic lupus erythematosus
    Acute rheumatic carditis
  4. Dermatologic Diseases:
    Pemphigus
    Bullous dermatitis herpetiformis
    Severe erythema multiforme (Stevens-Johnson syndrome)
    Exfoliative dermatitis
    Mycosis fungoides
    Severe psoriasis
    Severe seborrheic dermatitis
  5. Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment:
    Seasonal or perennial allergic rhinitis
    Bronchial asthma
    Contact dermatitis
    Atopic dermatitis
    Serum sickness
    Drug hypersensitivity reactions
  6. Ophthalmic Diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as:
    Allergic conjunctivitis
    Keratitis
    Allergic corneal marginal ulcers
    Herpes zoster ophthalmicus
    Iritis and iridocyclitis
    Chorioretinitis
    Anterior segment inflammation
    Diffuse posterior uveitis and choroiditis
    Optic neuritis
    Sympathetic ophthalmia
  7. Respiratory Diseases:
    Symptomatic sarcoidosis
    Loeffler's syndrome not manageable by other means
    Berylliosis
    Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy
    Aspiration pneumonitis
  8. Hematologic Disorders:
    Idiopathic thrombocytopenic purpura in adults
    Secondary thrombocytopenia in adults
    Acquired (autoimmune) hemolytic anemia
    Erythroblastopenia (RBC anemia)
    Congenital (erythroid) hypoplastic anemia
  9. Neoplastic Diseases: For palliative management of:
    Leukemia and lymphomas in adults
    Acute leukemia of childhood
  10. Edematous States: To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus
  11. Gastrointestinal Diseases: To tide the patient over a critical period of the disease in:
    Ulcerative colitis
    Regional enteritis
  12. Miscellaneous:
    Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy
    Trichinosis with neurologic or myocardial involvement
  13. Diagnostic testing of adrenocortical hyperfunction.

Contraindications

Systemic fungal infections

Hypersensitivity to this product

Precautions

Following prolonged therapy, withdrawal of corticosteroids may result in symptoms of the corticosteroid withdrawal syndrome including fever, myalgia, arthralgia, and malaise. This may occur in patients even without evidence of adrenal insufficiency.

There is an enhanced effect of corticosteroids in patients with hypothyroidism and in those with cirrhosis.

Corticosteroids should be used cautiously in patients with ocular herpes simplex because of possible corneal perforation.

The lowest possible dose of corticosteroid should be used to control the condition under treatment, and when reduction in dosage is possible, the reduction should be gradual.

Psychic derangements may appear when corticosteroids are used, ranging from euphoria, insomnia, mood swings, personality changes, and severe depression, to frank psychotic manifestations. Also, existing emotional instability or psychotic tendencies may be aggravated by corticosteroids.

Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia.

Steroids should be used with caution in nonspecific ulcerative colitis, if there is a probability of impending perforation, abscess, or other pyogenic infection, diverticulitis, fresh intestinal anastomoses, active or latent peptic ulcer, renal insufficiency, hypertension, osteoporosis and myasthenia gravis. Signs of peritoneal irritation following gastrointestinal perforation in patients receiving large doses of corticosteroids may be minimal or absent. Fat embolism has been reported as a possible complication of hypercortisonism.

When large doses are given, some authorities advise that corticosteroids be taken with meals and antacids taken between meals to help to prevent peptic ulcer.

Growth and development of infants and children on prolonged corticosteroid therapy should be carefully observed.

Steroids may increase or decrease motility and number of spermatozoa in some patients.

Phenytoin, phenobarbital, ephedrine, and rifampin may enhance the metabolic clearance of corticosteroids, resulting in decreased blood levels and lessened physiologic activity, thus requiring adjustment in corticosteroid dosage. These interactions may interfere with dexamethasone suppression tests which should be interpreted with caution during administration of these drugs.

False-negative results in the dexamethasone suppression test (DST) in patients being treated with indomethacin have been reported. Thus, results of the DST should be interpreted with caution in these patients.

The prothrombin time should be checked frequently in patients who are receiving corticosteroids and coumarin anticoagulants at the same time because of reports that corticosteroids have altered the response to these anticoagulants. Studies have shown that the usual effect produced by adding corticosteroids is inhibition of response to coumarins, although there have been some conflicting reports of potentiation not substantiated by studies.

When corticosteroids are administered concomitantly with potassium-depleting diuretics, patients should be observed closely for development of hypokalemia.

Store at 20˚-25˚C (68˚-77˚F) [See USP Controlled Room Temperature].

KEEP TIGHTLY CLOSED

AVOID FREEZING

Dispense in a tight container as defined in the USP.

Rx Only

Manufactured for:

Pragma Pharmaceuticals, LLC

Locust Valley, NY 11560

Distributed by:

Fera Pharmaceuticals, LLC

Locust Valley, NY 11560

R0-7/17 PPI-010, Rev. 0717
DO NOT USE IF BAND PRINTED “SEALED FOR YOUR PROTECTION” AROUND CAP IS BROKEN OR MISSING.

Each 5 mL (teaspoonful) contains:

Dexamethasone, USP ................................................................... 0.5 mg

Also contains:

Benzoic Acid, USP (as preservative) ................................................. 0.1%

Alcohol (% v/v) ................................................................................ 5.1%

USUAL ADULT DOSAGE: See accompanying package insert.

WARNINGS: KEEP THIS AND ALL DRUGS OUT OF THE REACH OF CHILDREN. In case of accidental overdose, seek professional assistance or contact a Poison Control Center immediately.

Store at 20° – 25°C (68° – 77°F)

[see USP Controlled Room Temperature].

KEEP TIGHTLY CLOSED

AVOID FREEZING

Dispense in a tight container as defined in the USP.

Manufactured for:

Pragma Pharmaceuticals, LLC

Locust Valley, NY 11560

Distributed by:

Fera Pharmaceuticals, LLC

Locust Valley, NY 11560

R0-7/17

Principal Display Panel - Decadron Bottle Label

NDC 58463-010-08

DECADRON®

Dexamethasone Elixir, USP

0.5 mg/5 mL

Contains 5.1% Alcohol (% v/v)

NET: 8 fl oz (237 mL) Rx only

Pragma®

DECADRON 
dexamethasone elixir
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:58463-010
Route of Administration ORAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
dexamethasone (dexamethasone) dexamethasone 0.5 mg  in 5 mL
Inactive Ingredients
Ingredient Name Strength
alcohol  
benzoic acid  
citric acid monohydrate  
FD&C red no. 40  
propylene glycol  
raspberry  
sucrose  
trisodium citrate dihydrate  
water  
Product Characteristics
Color      Score     
Shape Size
Flavor RASPBERRY (RASPBERRY) Imprint Code
Contains     
Packaging
# Item Code Package Description
1 NDC:58463-010-08 237 mL in 1 BOTTLE
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA090891 03/15/2018
Labeler - Pragma Pharmaceuticals, LLC (078813515)
Revised: 10/2017   Pragma Pharmaceuticals, LLC
(web3)